Prevention of chemotherapy-induced nausea and vomiting: Focus on fosaprepitant

Therapeutics and Clinical Risk Management

Volumn 4, Issue 2, 2008, Pages 501-506

  Olver, Ian N ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NONE   (Australia)

Author keywords

Aprepitant; Chemotherapy; Emesis; Fosaprepitant; Neurokinin receptor

Indexed keywords

2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; APREPITANT; ASTEMIZOLE; CISAPRIDE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450 3A; DEXAMETHASONE; GRANISETRON; MK 0517; NEUROKININ 1 RECEPTOR; ONDANSETRON; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PIMOZIDE; PLACEBO; PRODRUG; RAPAMYCIN; TACROLIMUS; TOLBUTAMIDE; WARFARIN;

ANOREXIA; ANTIEMETIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BIOEQUIVALENCE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DYSPEPSIA; FATIGUE; FLUSHING; HICCUP; HUMAN; INFUSION RATE; MENSTRUATION DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PATIENT SATISFACTION; PHLEBITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE;

EID: 44049092242     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Andrews PI, Naylor RJ, Joss RA. 1998. Neuropharmacology of vomiting and its relevance to anti-emetic therapy. Consensus and controversies. Support Care Cancer, 6:197-203.
2. Bergman AJ, Marbury T, Fosbinder T, et al. 2005. Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant. Clin Pharmacokinet, 44:637-47.
3. Blum RA, Majumdar A, McCrea J, et al. 2003. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther, 25:1407-19.
4. Boer-Dennert M, Wit R, Schmitz PJ, et al. 1997. Patient perceptions of the side effects of chemotherapy: the influence of the 5-HT3 antagonists. Br J Cancer, 76:1055-61.
5. Campos D, Pereira JR, Reinhardt RR, et al. 2001. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol, 19:1759-67.
6. 1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer, 97:2290-300.
7. Cocquyt V, Van Belle S, Reinhardt RR, et al. 2001. Comparison of L-758,298 a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin induced emesis. Eur J Cancer, 37:835-42.
8. De Jonge ME, Huitema AD, Holtkamp MJ, et al. 2005. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol, 56:370-8.
9. Depre M, Van Hecken A, Oeyen M, et al. 2005. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol, 61:341-6.
10. 1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol, 21:4105-19.
11. Gralla RJ, Osoba D, Kris MG, et al. 1999. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol, 17: 2971-94.
12. Grote T, Hajdenberg J, Cartmell A, et al. 2006. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol, 4:403-8.
13. Grunberg SM, Deuson RR, Mavros P, et al. 2004. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer, 100:2261-8.
14. Hale JJ, Mills SG, MacCoss M, et al. 2000. Phosphorated morpholine acetal human neurokinin-1 receptor antagonists as water soluble prodrugs. J Med Chem, 43:1234-41.
15. Hargreaves R. 2002. Imaging substance P receptors (NK1) in the living human brain using positrom emission tomography. J Clin Psychiatry, 63:18-24.
16. Herrstedt J, Muss HB, Warr DG, et al. 2005. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer, 104:1548-55.
17. Hesketh PA. 1999. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist, 4:191-6.
18. Hesketh PJ, Grunberg SM, Gralla RJ, et al. 2003. The oral neurokinin-1 antagonists aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. The aprepitant protocol 052 study group. J Clin Oncol, 21:4112-9.
19. Hesketh PJ, Grunberg SM, Herrstedt J, et al. 2006. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer, 14:354-60.
20. Kris MG, Gralla RJ, Clark RA, et al. 1985. Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol, 3:1379-84.
21. Kris MG, Cubeddu LX, Gralla RJ, et al. 1996. Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer, 78:2193-8.
22. Lasseter KC, Gambale J, Jin B, et al. 2007. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol, 47:834-40.
23. Loos WJ, de Wit R, Freedman SJ, et al. 2007. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol, 59:407-12.
24. McCrea JB, Majumdar AK, Goldberg MR, et al. 2003. Effects of the neurokinin 1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharm Ther, 74:17-24.
25. Ma JG, Martin AR, Carides AD, et al. 2003. The oral NK1 antagonist, aprepitant, is effective in reducing impact of chemotherapy-induced nausea and vomiting on daily life in both younger and older patients receiving highly emetogenic chemotherapy. Proc Am Soc Clin Oncol, 22:785.
26. Martin AR, Carides AD, Pearson JD, et al. 2003. Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. Eur J Cancer, 39:1395-401.
27. Merck and Co Inc. 2007. Product Information. Emend IV™ (fosaprepitant dimeglumine, MSD) Approved by TGA Therapeutics Goods Administration 14 Aug 2007.
28. Moore S, Tumeh J, Wojtanowski S, et al. 2007. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value Health, 10:23-31.
29. Morrow GR. 1982. Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Instit, 68:585-93.
30. Navari RM, Reinhardt RR, Gralla RJ, et al. 1999. Reduction of cisplatin-induced emesis by a selective neurokinin-1 receptor antagonist. N Engl J Med, 340:190-5.
31. Navari RM. 2007. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs, 16:1977-85.
32. Nygren P, Hande K, Petty KJ, et al. 2005. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol, 55:609-16.
33. Oechsle K, Muller MR, Hartmann JT, et al. 2006. Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT (3) antagonists and dexamethasone. Onkologie, 29:557-61.
34. Olver I, Paska W, Depierre A, et al. 1996. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol, 7:945-52.
35. Olver I, Shelukar S, Thompson K. 2007. Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant. Int J Nanomedicine, 2:13-18.
36. Osoba D, Zee B, Warr D, et al. 1997. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of life and symptom control committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer, 5:307-13.
37. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. 2003. Addition of the neurokinin 1 antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer, 97:3090-8.
38. Schmoll HJ, Aapro MS, Poli-Bigelli, et al. 2006. Comparison of aprepitant regimes with a multiple day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol, 17:1000-6.
39. Shah AK, Hunt TL, Gallagher SC, et al. 2005. Pharmacokinetics of palonosetron in combinations with aprepitant in healthy volunteers. Curr Med Res Opin, 21:595-601.
40. Smith AR, Repka TL, Weigel BJ. 2005. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents. Pediatr Blood Cancer, 45:857-60.
41. Tattersall FD, Rycroft W, Cumberbatch M, et al. 2000. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology, 39:652-63.
42. Van Belle S, Lichinister MR, Navari RM, et al. 2002. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869: a randomized controlled trial. Cancer, 94:3032-41.
43. Warr DG, Hesketh PJ, Gralla RJ, et al. 2005. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emtogenic chemotherapy. J Clin Oncol, 23:2882-30.
44. Watson JW, Gonsalves SF, Rossa AA, et al. 1998. The antiemetic effects of CP-99,994 in the ferret and dog: role of the NK-1 receptor. Br J Pharmacol, 115:84-94.